Carbamazepine and Blood immunoglobulin m decreased - a phase IV clinical study of FDA data

Summary:

Blood immunoglobulin m decreased is found among people who take Carbamazepine, especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Carbamazepine and have Blood immunoglobulin m decreased. It is created by eHealthMe based on reports of 38,703 people who have side effects when taking Carbamazepine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

38,703 people reported to have side effects when taking Carbamazepine.
Among them, 17 people (0.04%) have Blood immunoglobulin m decreased.


What is Carbamazepine?

Carbamazepine has active ingredients of carbamazepine. It is often used in epilepsy. eHealthMe is studying from 39,566 Carbamazepine users for its effectiveness, alternative drugs and more.

What is Blood immunoglobulin m decreased?

Blood immunoglobulin m decreased is found to be associated with 422 drugs and 189 conditions by eHealthMe.

Number of Carbamazepine and Blood immunoglobulin m decreased reports submitted per year:

Could Carbamazepine cause Blood immunoglobulin m decreased?

Time on Carbamazepine when people have Blood immunoglobulin m decreased *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Blood immunoglobulin m decreased when taking Carbamazepine *:

  • female: 58.82 %
  • male: 41.18 %

Age of people who have Blood immunoglobulin m decreased when taking Carbamazepine *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 12.5 %
  • 30-39: 6.25 %
  • 40-49: 50.0 %
  • 50-59: 25.0 %
  • 60+: 6.25 %

Common drugs people take besides Carbamazepine *:

  1. Valproate Sodium: 2 people, 11.76%
  2. Paxil: 2 people, 11.76%
  3. Ocrevus: 2 people, 11.76%
  4. Zofran: 1 person, 5.88%
  5. Besivance: 1 person, 5.88%
  6. Dexedrine: 1 person, 5.88%
  7. Cyanocobalamin: 1 person, 5.88%
  8. Clonazepam: 1 person, 5.88%
  9. Clomipramine Hydrochloride: 1 person, 5.88%
  10. Centrum Silver: 1 person, 5.88%

Common side effects people have besides Blood immunoglobulin m decreased *:

  1. Blood Immunoglobulin G Decreased: 15 people, 88.24%
  2. Hypogammaglobulinaemia (an abnormally low concentration of gamma globulin in the blood and increased risk of infection): 7 people, 41.18%
  3. Blood Immunoglobulin A Decreased: 6 people, 35.29%
  4. Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 5 people, 29.41%
  5. B-Lymphocyte Count Decreased: 5 people, 29.41%
  6. Itching: 5 people, 29.41%
  7. Rashes (redness): 4 people, 23.53%
  8. Fever: 4 people, 23.53%
  9. Alanine Aminotransferase Increased: 4 people, 23.53%
  10. Eosinophilia (eosinophil count in the peripheral blood exceeds): 4 people, 23.53%

Common conditions people have *:

  1. Serum Ferritin Decreased: 1 person, 5.88%
  2. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 5.88%
  3. Pain: 1 person, 5.88%
  4. Osteoarthritis (a joint disease caused by cartilage loss in a joint): 1 person, 5.88%
  5. Obsessive-Compulsive Disorder (an anxiety disorder characterized by intrusive thoughts that produce uneasiness, apprehension, fear, or worry;): 1 person, 5.88%
  6. Neuralgia (pain in one or more nerves): 1 person, 5.88%
  7. Nausea (feeling of having an urge to vomit): 1 person, 5.88%
  8. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.88%
  9. Migraine (headache): 1 person, 5.88%
  10. Menopause (end of monthly cycles in women): 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Carbamazepine and have Blood immunoglobulin m decreased?

Check whether Blood immunoglobulin m decreased is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

How severe was Blood immunoglobulin m decreased and when was it recovered:

Expand to all the drugs that have ingredients of carbamazepine:

Alternative drugs to, pros and cons of Carbamazepine:

Common Carbamazepine side effects:

Browse all side effects of Carbamazepine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Blood immunoglobulin m decreased treatments and more:

COVID vaccines that are related to Blood immunoglobulin m decreased:

All the drugs that are associated with Blood immunoglobulin m decreased:

All the conditions that are associated with Blood immunoglobulin m decreased:

How the study uses the data?

The study uses data from the FDA. It is based on carbamazepine (the active ingredients of Carbamazepine) and Carbamazepine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: